News und Analysen

A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs

As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint

Nvidia (NASDAQ: NVDA) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a

With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could

A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its

Shares of Medtronic (NYSE: MDT) responded poorly to the company's latest quarterly results announcement. The market knocked the stock about 5% lower on May 23, but some analysts who follow the

The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future

When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We

What's better than a stock that has delivered huge gains? That's easy: A stock that has delivered huge gains and still has a lot of room to run.

We asked three Motley Fool contributors to look among

Relax, do what you enjoy, and rake in money. That probably sounds like a great life for most people. Making it a reality isn't easy, but it's possible.

The key is to generate passive income. You'll

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q4 2024 Earnings CallMay 23, 2024, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Medtronic (NYSE: MDT) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.

Heading into earnings, analysts had the medical

The Great Recession ended nearly 15 years ago. Buying stocks toward the end of an economic slowdown can lead to some oversize returns down the road since that usually means you're buying them at

When it comes to investing, I often look for companies that generate strong amounts of free cash flow (FCF), and companies that can grow their FCF. One company that has proven that over the years is

There are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it

The past couple of years haven't been easy ones to be a Pfizer (NYSE: PFE) shareholder. The windfall profits its COVID-19 products produced in the early days of the pandemic evaporated much faster

Wall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far.

Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen

Investors looking to pad their passive income streams with high-yield dividend stocks have three excellent choices. If you have an extra $100 to invest, you could set yourself up with dividends from

Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight

CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for

The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You

Dividend stocks tend to struggle in high-interest-rate environments. The core reason is investors have an abundance of low-risk, high-yield income options when interest rates spike.

Conversely, fund

Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.

Eli Lilly (NYSE: LLY) and Regeneron